News

Under the terms of the agreement, Teva will acquire 100% of the shares of Barr for total cash and stock consideration of $7.46 billion. Each share of Barr’s

The ViroSeq HIV-1 genotyping system is said to be designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as

Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). In October 2007, Abraxane was approved by

The transaction is expected to complete by early August, 2008. The financial details of the agreement were not disclosed. Daiichi Sankyo said that the transaction may affect about

The lead investors were CHL Medical Partners and Foundation Medical Partners and were joined in the round by previous investors Aweida Venture Partners and DFJ Mercury. In connection

In December 2007, Lilly and Galapagos initiated a program to develop new medicines for the treatment of osteoporosis. The agreement provides Lilly access to 12 of Galapagos’s novel

This follows on from the completion of several oral feasibility studies combining Merrion’s Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation

Biovest reported on two clinically relevant data points – overall median disease-free survival data as measured up to 80 months; and disease-free survival data on these same patients

The Mindset-01 Phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 (dirucotide) in patients with relapsing-remitting multiple sclerosis. The fifteen month trial